RxDoctor Payments Data

Jeffrey Langford, MD

Allergy & Immunology · Macon, GANPI 1346360690

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by GSK at 30.7% of the total. 2025 is the largest year on record at $4,846, 4.3 times the $1,125 reported in 2019.

$12,924in general payments, 2019–2025

Across 105 payments — averaging $123.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • Sanofi$3K
  • AstraZeneca$2K
  • Novartis$2K
  • Regeneron Healthcare Solutions, Inc.$974
  • Octapharma USA, Inc.$852
  • plus $852 from 13 others

What the payments were for

  • Consulting fees$6,95154%
  • Food & beverage$5,94046%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,924 in reported general payments places this provider in the 75th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,659,558
Medicare patients
208
Services billed
68,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter248$286,775
HizentraImmun Glob G(Igg)/Pro/Iga 0-5026$205,774
XolairOmalizumab24$83,073
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$77,410
Dupixent PenDupilumab13$48,646
Breo ElliptaFluticasone/Vilanterol71$43,414
Spiriva RespimatTiotropium Bromide45$42,816
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$34,828
Epinephrine152$29,584
SymbicortBudesonide/Formoterol Fumarate45$15,708
Ipratropium Bromide234$10,390
Advair HfaFluticasone Propion/Salmeterol18$9,445
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$9,274
DuleraMometasone/Formoterol18$7,683
Azelastine Hcl210$6,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$3,970$334,468334 claims
Grifols USA, LLCGamunex-C$45$77,41012 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,934$50,53691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →